Launch of Phase 3 clinical trial with Nefecon in Japan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 04 2024
0mins
Should l Buy ?
Source: Newsfilter
- Calliditas Therapeutics Announcement: Calliditas Therapeutics AB partners with Viatris Pharmaceutical Japan G.K. to conduct a phase III clinical trial in Japan for IgA nephropathy.
- Clinical Trial Details: The trial, named VR-205 in Japan, aims to study Japanese patients with IgA nephropathy, a retractable disease in Japan with limited treatment options.
- Bridging Study: The trial is a bridging study requiring Japanese patients to participate in a design similar to the global NefIgArd trial.
- License Agreement: Calliditas Therapeutics announces a license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan.
- Contact Information: For more information, individuals can contact Åsa Hillsten, Head of IR & Sustainability at Calliditas, via phone at +46 76 403 35 43 or email at [email protected]
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
